Product Information
BUPRENORPHINE 2 MG TABLET SL is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $0.2768 per EA under NDC 42858050103. Its NADAC has been published 446 times since Mar 21, 2018.
FDA first approved this application on Mar 27, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858050103
Classification
Generic
Dosage Form
TABLET
Route
SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207276FDA Approved
3/27/2017
TE Code
AB
On Market Since
10/25/2017
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE 2 MG TABLET SL has been published 446 times since Mar 21, 2018, and over the history we have for it it has declined 70.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2768 per EA |
|---|---|
| All-time high | $0.9445 (Apr 11, 2018) |
| All-time low | $0.2629 (Jun 17, 2026) |
| 52-week high | $0.3100 |
| 52-week low | $0.2629 |
| Median price | $0.4641 |
| Average price | $0.4904 |
| Largest weekly change | +42.0% (Aug 21, 2024) |
| Weeks tracked | 446 |
| Tracking since | Mar 21, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BUPRENORPHINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
BUPRENORPHINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Partial Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE 2 MG TABLET SL?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE 2 MG TABLET SL, manufactured by Rhodes Pharmaceuticals L.P., is $0.2768 per EA (NDC 42858050103), effective Sep 30, 2026.
How has the price of BUPRENORPHINE 2 MG TABLET SL changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE 2 MG TABLET SL has declined 70.7%. It has been tracked across 446 weekly CMS publications since Mar 21, 2018.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE 2 MG TABLET SL?
Since Mar 21, 2018, the NADAC for BUPRENORPHINE 2 MG TABLET SL has ranged from a low of $0.2629 (Jun 17, 2026) to a high of $0.9445 (Apr 11, 2018), with a median of $0.4641 per EA.
Are there cheaper alternatives to BUPRENORPHINE 2 MG TABLET SL?
No other NADAC-published product currently shares the active ingredient and strength of BUPRENORPHINE 2 MG TABLET SL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUPRENORPHINE 2 MG TABLET SL?
BUPRENORPHINE 2 MG TABLET SL (NDC 42858050103) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.